Clinical trials: Active Cancer
Multiple Myeloma
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone [Len/Dex (Treatment A)] or Bortezomib Plus…
- Trial name
- DREAMM 6 (NCT03544281)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Lymphoma
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with…
- Trial name
- NCT02257567
- Testing
- Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid)
- Where
- 62 sites in United States, Australia and 11 more
- Volunteers
- 331 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
This is a pilot evaluation of a patient-centered intervention that enables providers to support men on active surveillance to maximize adherence.
- Trial name
- NCT05764005
- Testing
- web-based tool (MAP- Management of Active surveillance in Prostate Cancer), MUSIC website
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Michigan Rogel Cancer Center
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
- Trial name
- NCT04303780
- Testing
- AMG 510, Docetaxel
- Where
- 274 sites in United States, Australia and 21 more
- Volunteers
- 345 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of Lazertinib when given orally to participants with epidermal growth factor receptor single activating mutation positive (EGFRm+)…
- Trial name
- NCT04075396
- Testing
- Lazertinib
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone.
- Trial name
- NCT01339260
- Testing
- Netupitant and Palonosetron, Palonosetron, Dexamethasone
- Where
- 172 sites in United States, Argentina and 13 more
- Volunteers
- 1,455 people
- Sponsor
- Helsinn Healthcare SA
Multiple Myeloma
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure.
- Trial name
- NCT04177823
- Testing
- Belantamab mafodotin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Advanced Cancer, Cervical Cancer
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent…
- Trial name
- NCT03104699
- Testing
- AGEN2034
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 211 people
- Sponsor
- Agenus Inc.
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Glioblastoma Multiforme
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).
- Trial name
- NCT00093964
- Testing
- Cilengitide 500 mg, Cilengitide 2000 mg
- Where
- 17 sites in United States
- Volunteers
- 81 people
- Sponsor
- EMD Serono
Colorectal Cancer, Neoplasms, Colorectal
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
This phase 2, randomized, active-controlled, open-label, parallel group, multicenter study will be conducted at up to 18 study centers in the US, Central America, and South America.
- Trial name
- NCT00967616
- Testing
- CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo
Melanoma
Melanoma Vaccine With Peptides and Leuprolide
The goal of this clinical research study is to learn if the drug leuprolide will increase the level of immune cells in your body.
- Trial name
- NCT00254397
- Testing
- Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate…
- Trial name
- NCT03262389
- Testing
- Fludeoxyglucose PET CT, Sodium Acetate C11 PET CT, Fludeoxyglucose PET MRI
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael C Roarke, MD
Solid Tumor, Adult
Study of ASTX029 in Subjects With Advanced Solid Tumors
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced…
- Trial name
- NCT03520075
- Testing
- ASTX029
- Where
- 31 sites in United States, France and 2 more
- Volunteers
- 192 people
- Sponsor
- Taiho Oncology, Inc.
Early Breast Cancer
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
This is a multi-center, open-label Phase II randomized pre-surgical pharmacodynamics study.
- Trial name
- MONALEESA-1 (NCT01919229)
- Testing
- LEE011 (ribociclib), letrozole
- Where
- 7 sites in United States, Singapore and 1 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
- Trial name
- MEDI-575 (NCT00816400)
- Testing
- MEDI-575
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Prostate Adenocarcinoma
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells.
- Trial name
- NCT02721979
- Testing
- Apalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Cardiac Toxicity, Malignant Neoplasm
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy.
- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Trial name
- NCT01719562
- Testing
- Magnetic resonance imaging, Physical Activity, Healthy Living
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Renal Cell Carcinoma
Neoadjuvant Pazopanib in Renal Cell Carcinoma
This study will be a single arm phase II clinical trial of 8 weeks of daily, oral neo-adjuvant pazopanib prior to nephrectomy in 39 evaluable patients with histologically confirmed localized renal cell carcinoma (RCC).
- Trial name
- NCT01361113
- Testing
- Pazopanib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences